Adaptimmune Therapeutics Plc Profit Margin

The latest profit margin for ADAP is -2.61% as of June 2025. That compares with -51.44% in the prior-year period — down 407.1% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Adaptimmune Therapeutics Plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADAP's profit margin moved from -51.44% to -2.61% — a 407.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adaptimmune Therapeutics Plc's valuation or profitability profile.

Against Healthcare companies, ADAP currently prints -2.61% for profit margin, while the sector average sits near 15.58%. That is roughly 1773.6% below the sector mean. Large gaps often invite a closer look at Adaptimmune Therapeutics Plc's growth, margins, and balance sheet.

Profit Margin shows how effectively Adaptimmune Therapeutics Plc converts resources into returns. At -2.61%, ADAP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -51.44% in the prior-year period — down 407.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADAP's profit margin (-2.61%), review year-over-year change from -51.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.